BMS to beef up portfolio of diabetes medicines

Published: 2012-09-11 06:57:00

Updated: 2012-09-11 06:57:00

U.S. based Bristol-Myers Squibb (BMS) is set to increase and promote its innovative portfolio of diabetes medicines, extending its reach across the spectrum of treatment options.

Both BMS and AstraZeneca successfully completed the acquisition of Amylin Pharmaceuticals last month. AstraZeneca m...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK